ArticleIranian journal of basic medical sciences2025
Troxerutin attenuates LPS-induced inflammation in BV2 microglial cells involving Nrf2 activation and NF-κB pathway inhibition.
Article in Iranian journal of basic medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Microglial cell-mediated neuroinflammation is a key driver of central nervous system (CNS) homeostasis and a significant risk factor for neurodegeneration and development of neurological diseases. We assessed whether troxerutin (TX) exerts anti-neuroinflammatory effects in lipopolysaccharide (LPS)-stimulated BV2 microglia and explored its mechanism. Materials and Methods: To investigate the suppressive action of TX on M1 polarization, BV2 cells were stimulated with LPS and then treated with TX or minocycline (MINO). Cell viability was assessed via Cell Counting Kit-8 (CCK-8), and inflammatory cytokines were measured by quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA). Furthermore, the nuclear factor erythroid 2-related factor 2 (Nrf2)/nuclear factor-kappa B (NF-κB) signaling pathway was analyzed by Western blotting (WB) to elucidate the molecular mechanism of the anti-neuroinflammatory activity of TX. Results: TX inhibited the expression of interleukin-6 (IL-6) and interleukin-1β (IL-1β), as well as the secretion of IL-6 and tumor necrosis factor-α (TNF-α). Additionally, TX accelerated the release of transforming growth factor-β (TGF-β) and cluster of differentiation 206 (CD206) in BV2 microglia exposed to LPS. TX regulated the neuroinflammatory response by blocking phosphorylation of NF-κB and inhibitor of kappa B alpha (IκBα) mediated by LPS stimulation and inducing Nrf2 and heme oxygenase-1 (HO-1) protein expression. Conclusion: TX suppresses pro-inflammatory induction after LPS stimulation of BV2 microglia, which may be related to the NF-κB inhibition and accelerated HO-1/Nrf2 activation. These findings pinpoint the potential therapeutic potential of TX in inflammation-induced neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.